Paul LaViolette
Paul LaViolette
dealing flaws precedent system
We see real flaws in the method. We're not dealing with a system that has a lot of precedent and has a lot of transparency.
provide run
We're going to run some new plays, and we think they're going to provide us some more momentum.
asset boston key scientific
What we get is diversification for Boston Scientific and growth, and we get that through CRM. Clearly, CRM is the key asset here.